A panel of biologically contained orthoebolaviruses for the screening of broad-spectrum antivirals
Preprint
Abstract
Filoviruses, particularly those of the Orthoebolavirus genus, pose ongoing public health threats due to their increasing frequency and geographic spread. However, research has been impeded by the biosafety level 4 classification of filoviruses. We previously reported the generation of biologically contained Ebola, Marburg and Sudan virus as lower biosafety level-compatible filovirus systems. In the present study, we expanded this repertoire to include biologically contained Taï Forest, Bundibugyo and Reston virus, thereby creating a near-complete toolkit for currently recognized human-relevant orthoebolaviruses. VP30-deficient viruses were generated with matching VP30 expressing cell lines. More specifically, we developed and optimized a dual-reporter system in VeroE6, Huh-7 and A549 cells, combining a virus-encoded enhanced green fluorescent protein reporter as readout for viral replication with a stably cellular-expressed nuclear mCherry marker for cytotoxicity assessment. Next, we screened two repurposing-oriented compound libraries comprising 640 small molecules against Taï Forest, Bundibugyo and Sudan virus, and subsequently cross-validated against Reston and Ebola virus. This approach identified multiple candidates with broad-spectrum activity across orthoebolaviruses, while also revealing virus-specific antivirals, with robust activity observed in both primate- and human-derived cell lines. Together, this work establishes a versatile and experimentally tractable lower biosafety level-compatible platform for the study of human-relevant orthoebolaviruses and the systematic discovery of broad-spectrum antiviral countermeasures against filoviruses.Keywords
This publication has 63 references indexed in Scilit:
- Generation of a VeroE6 Pgp gene knock out cell line and its use in SARS-CoV-2 antiviral studyAntiviral Research, 2022
- Development and optimization of biologically contained Marburg virus for high-throughput antiviral screeningAntiviral Research, 2022
- Identification of novel Ebola virus inhibitors using biologically contained virusAntiviral Research, 2022
- Grand Challenges in Pharmaceutical Research Series: Ridding the Cold Chain for BiologicsPharmaceutical Research, 2021
- Characterization of Reston virus infection in ferretsAntiviral Research, 2019
- Bushmeat and Emerging Infectious Diseases: Lessons from Africa2015
- “Filoviruses”: a real pandemic threat?EMBO Molecular Medicine, 2009
- Z-Factor2008
- Peptidyl fluoromethyl ketones as inhibitors of cathepsin B: Implication for treatment of rheumatoid arthritisBiochemical Pharmacology, 1992
- Preliminary report: isolation of Ebola virus from monkeys imported to USAThe Lancet, 1990